Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Clinical trial NCT06043427 · RECRUITING

Trial details

NCT number: NCT06043427
Sponsor: Canadian Cancer Trials Group
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastroesophageal Adenocarcinoma

Start date: 2024-04-16
Primary completion: 2026-12-31
Enrollment: 168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.